The continuing challenge of hepatic cancer in Asia
The continuing challenge of hepatic cancer in Asia
复制标题
DOI：
10.1016/s1479-666x(05)80043-5
复制
发表时间：
2005-06-01
影响因子：
2.5
通讯作者：
Lau, WY
中科院分区：
文献类型：
--
作者：
Lai, ECH;Lau, WY
肝细胞癌（HCC）是世界上第五大常见癌症。新病例估计为每年564 000例。大约80%的病例发生在亚洲。HCC管理的目标是“癌症控制”-降低其发病率和死亡率，以及改善HCC患者及其家人的生活质量。总体而言，80%的HCC可归因于慢性B和C型肝炎感染。预防B和C型肝炎病毒感染是降低亚洲HCC发病率的关键策略。肝切除和肝移植仍然是最有可能治愈的选择。在过去的二十年里，手术死亡率和手术结果的肝切除和肝移植治疗肝癌已有所改善。综合治疗也取得了进展，可以增加晚期肝癌患者的生存机会，改善生活质量。亚洲地区仍面临许多挑战，如慢性肝炎的高患病率、肝癌的低切除率、术后高复发率和尸体器官供体的严重短缺。本文旨在讨论亚洲HCC预防和管理的发展和挑战。
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. The number of new cases is estimated to be 564,000 per year. About 80% of all cases are found in Asia. The goal of HCC management is "cancer control" - a reduction in its incidence and mortality as well as an improvement in the quality of life of patients with HCC and their family. Overall, 80% of HCC can be attributed to chronic hepatitis B and C infection. Prevention of infection with hepatitis B and C virus is the key strategy to reduce the incidence of HCC in Asia. Liver resection and liver transplantation remain the options that give the best chance of a cure. In the past two decades, operative mortality and surgical outcome of liver resection and liver transplantation for HCC have improved. Progress also has been made in multi-modality therapy which can increase the chance of survival and improve the quality of life for patients with advanced HCC. Many challenges are still present in Asia, such as the high prevalence of chronic hepatitis, the low resection rate of HCC, the high postoperative recurrence and the severe shortage of cadaveric organ donor. This article aims to discuss the development and challenges in the prevention and management of HCC in Asia.